Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mumps vaccine, live (human diploid cell)
- Development stage
- Phase 3
- Lead developer
- Institute of Medical Biology Chinese Academy of Medical Sciences
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The mumps vaccine, live (human diploid cell) is a monovalent, live attenuated vaccine developed by the Institute of Medical Biology at the Chinese Academy of Medical Sciences (IMBCAMS). This specific vaccine candidate is derived from an F-genotype mumps virus strain and is manufactured using a human diploid cell substrate (such as the KMB17 cell line), which is intended to offer improved purity and a lower risk of allergic reactions compared to traditional vaccines produced in chick embryo cells. The vaccine works by introducing a weakened form of the virus to stimulate the host's immune system, leading to the production of neutralizing antibodies and cellular immune responses against the mumps virus. It has been evaluated in Phase II/III clinical trials in China to assess its safety, immunogenicity, and clinical protective efficacy in healthy children aged 5 to 11 years.
- Other names
- F-genotype mumps live attenuated vaccine (human diploid cell)mumps vaccine, live
Beyond the preview
Go deeper on mumps vaccine, live (human diploid cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mumps vaccine, live (human diploid cell).